Multidrug Resistance Proteins in Primary and Metastatic Soft-tissue Sarcomas: Down-regulation of P-glycoprotein during Metastatic Progression

Anticancer Research

Volumn 24, Issue 1, 2004, Pages 291-295

  Komdeur, Rudy ^a   Molenaar, Willemina M ^a   Zwart, Nynke ^a   Hoekstra, Harald J ^a   Van Den Berg, Eva ^a   Van Der Graaf, Winette T A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Metastasis; Multidrug resistance; Soft tissue sarcomas

Indexed keywords

GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METASTASIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SCORING SYSTEM; SOFT TISSUE SARCOMA; TUMOR CELL; UPREGULATION;

DOWN-REGULATION; DRUG RESISTANCE, MULTIPLE; HUMANS; LYMPHATIC METASTASIS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; SARCOMA; SOFT TISSUE NEOPLASMS; UP-REGULATION; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 1442277078     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Fong Y, Coit DG, Woodruff JM and Brennan MF: Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg 217: 72-77, 1993.
2. Mazeron JJ and Suit HD: Lymph nodes as sites of metastases from sarcomas of soft tissue. Cancer 60: 1800-1808, 1987.
3. Jager PL, Hoekstra HJ, Leeuw J, van der Graaf WT, de Vries EG and Piers D: Routine bone scintigraphy in primary staging of soft tissue sarcoma; Is it worthwhile? Cancer 89: 1726-1731, 2000.
4. Mattern J and Volm M: Detection of resistance proteins in matched primary lung tumors and lymph node metastases. Anticancer Res 14: 417-419, 1994.
5. Sakamoto H, Kinoshita K, Nakayama Y, Takami T, Ohtani K, Izuka S and Satoh K: Gene expression in primary, metastatic and recurrent lesions of endometrial cancer. Gynecol Obstet Invest 48: 215-220, 1999.
6. Schadendorf D, Herfordt R and Czarnetzki BM: P-glycoprotein expression in primary and metastatic malignant melanoma. Br J Dermatol 132: 551-555, 1995.
7. Zochbauer-Muller S, Filipits M, Rudas M, Brunner R, Krajnik G, Suchomel R, Schmid K and Pirker R: P-glycoprotein and MRP1 expression in axillary lymph node metastases of breast cancer patients. Anticancer Res 21: 119-124, 2001.
8. Komdeur R, Plaat BE, van der Graaf WT, Hoekstra HJ, Hollema H, van den Berg E, Zwart N, Scheper RJ and Molenaar WM: Expression of multidrug resistance proteins, P-gp, MRP1 and LRP, in soft tissue sarcomas analysed according to their histological type and grade. Eur J Cancer 39: 909-916, 2003.
9. Weiss SW and Goldblum JR: Enzinger and Weiss's Soft Tissue Tumors. 4th Edition, 2001; St. Louis, Mosby.
10. Komdeur R, Plaat BEC, Hoekstra HJ, Molenaar WM, Hollema H, van den Berg E, Mastik MF and Van der Graaf WT: Expression of P-glycoprotein, multidrug resistance-associated protein 1, and lung resistance-related protein in human soft tissue sarcomas before and after hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Cancer 91: 1940-1948, 2001.
11. Bart J, Groen HJ, van der Graaf WT, Hollema H, Hendrikse NH, Vaalburg W, Sleijfer DT and De Vries EG: An oncological view on the blood-testis barrier. Lancet Oncol 3: 357-363, 2002.
12. Schinkel AH: The roles of P-glycoprotein and MRP1 in the blood-brain and blood-cerebrospinal fluid barriers. Adv Exp Med Biol 500: 365-372, 2001.
13. Chan HS, Thorner PS, Haddad G and Ling V: Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 8: 689-704, 1990.
14. Coley HM, Verrill MW, Gregson SE, Odell DE, Fisher C and Judson IR: Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma. Eur J Cancer 36: 881-888, 2000.
15. Jimenez RE, Zalupski MM, Frank JJ, Du W, Ryan JR and Lucas DR: Multidrug resistance phenotype in high grade soft tissue sarcoma: correlation of P-glycoprotein immunohistochemistry with pathologic response to chemotherapy. Cancer 86: 976-981, 1999.
16. Kuttesch JF, Parham DM, Luo X, Meyer WH, Bowman L, Shapiro DN, Pappo AS, Crist WM, Beck WT and Houghton PJ: P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma. J Clin Oncol 14: 886-900, 1996.
17. Levine EA, Holzmayer T, Bacus S, Mechetner E, Mera R, Bolliger C, Roninson IB and Das Gupta TK: Evaluation of newer prognostic markers for adult soft tissue sarcomas. J Clin Oncol 15: 3249-3257, 1997.
18. Nakanishi H, Myoui A, Ochi T and Aozasa K: P-glycoprotein expression in soft-tissue sarcomas. J Cancer Res Clin Oncol 123: 352-356, 1997.
19. Plaat BE, Hollema H, Molenaar WM, Torn Broers GH, Pijpe J, Mastik MF, Hoekstra HJ, van den Berg E, Scheper RJ and van der Graaf WT: Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 18: 3211-3220, 2000.
20. Stein U, Shoemaker RH and Schlag PM: MDR1 gene expression: evaluation of its use as a molecular marker for prognosis and chemotherapy of bone and soft tissue sarcomas. Eur J Cancer 32A: 86-92, 1996.
21. Kerbel RS, Kobayashi H and Graham CH: Intrinsic or acquired drug resistance and metastasis: are they linked phenotypes? J Cell Biochem 56: 37-47, 1994.
22. Weinstein RS, Jakate SM, Dominguez JM, Lebovitz MD, Koukoulis GK, Kuszak JR, Klusens LF, Grogan TM, Saclarides TJ, Roninson IB et al: Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 51: 2720-2726, 1991.
23. Tewari KS, Kyshtoobayeva AS, Mehta RS, Yu IR, Burger RA, DiSaia PJ and Fruehauf JP: Biomarker conservation in primary and metastatic epithelial ovarian cancer. Gynecol Oncol 78: 130-136, 2000.
24. Trammell RA, Johnson CB, Barker JR, Bell RS and Allan DG: Multidrug resistance-1 gene expression does not increase during tumor progression in the MGH-OGS murine osteosarcoma tumor model. J Orthop Res 18: 449-455, 2000.
25. Borst P, Evers R, Kool M and Wijnholds J: The multidrug resistance protein family. Biochim Biophys Acta 1461: 347-357, 1999.
26. Oda Y, Schneider-Stock R, Rys J, Gruchala A, Niezabitowski A and Roessner A: Expression of multidrug-resistance-associated protein gene in human soft-tissue sarcomas. J Cancer Res Clin Oncol 122: 161-165, 1996.
27. Harada T, Ogura S, Yamazaki K, Kinoshita I, Itoh T, Isobe H, Yamashiro K, Dosaka-Akit H and Nishimura M: Predictive value of expression of P53, Bcl-2 and lung resistance related protein for response to chemotherapy in non-small cell lung cancers. Cancer Sci 94: 394-399, 2003.
28. Kitazono M, Sumizawa T, Takebayashi Y, Chen ZS, Furukawa T, Nagayama S, Tani A, Takao S, Aikou T and Akiyama S: Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. J Natl Cancer Inst 91: 1647-1653, 1999.
29. Mossink MH, van Zon A, Franzel-Luiten E, Schoester M, Kickhoefer VA, Scheffer GL, Scheper RJ, Sonneveld P and Wiemer EA: Disruption of the murine major vault protein (MVP/LRP) gene does not induce hypersensitivity to cytostatics. Cancer Res 62: 7298-7304, 2002.
30. Scheffer GL, Schroeijers AB, Izquierdo MA, Wiemer EA and Scheper RJ: Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr Opin Oncol 12: 550-556, 2000.
31. Nijhuis PH, Schaapveld M, Otter R, Molenaar WM, van der Graaf WT and Hoekstra HJ: Epidemiological aspects of soft tissue sarcomas (STS)-consequences for the design of clinical STS trials. Eur J Cancer 35: 1705-1710, 1999.
32. Klunder JW, Komdeur R, van der Graaf WT, De Bont EJ, Hoekstra HJ, van den Berg E and Molenaar WM: Expression of multidrug resistance-associated proteins in rhabdomyosarcomas before and after chemotherapy: the relationship between lung resistance-related protein (LRP) and differentiation. Hum Pathol 34: 150-155, 2003.
33. van Geel AN, Pastorino U, Jauch KW, Judson IR, van Coevorden F, Buesa JM, Nielsen OS, Boudinet A, Tursz T and Schmitz PI: Surgical treatment of lung metastases: The European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patients. Cancer 77: 675-682, 1996.
34. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, Mouridsen H, Crowther D, Somers R, Verweij J, Santoro A, Buesa J and Tursz T: Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens. A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 17: 150-157, 1999.